Literature DB >> 19733925

Usefulness of minimal modelling to assess impaired insulin sensitivity in patients with chronic heart failure.

Tibor Szabo1, Stephan von Haehling, Dirk Habedank, Mathias Rauchhaus, Mitja Lainscak, Anja Sandek, Jörg Schefold, Stefan D Anker, Wolfram Doehner.   

Abstract

BACKGROUND: In chronic heart failure (CHF), impaired insulin sensitivity (Si) is frequently observed. It is associated with symptomatic status and poor prognosis suggesting an intrinsic role of Si within CHF pathophysiology. HOmeostasis Model Assessment (HOMA), Fasting Insulin Resistance Index (FIRI), and QUick Insulin CheCK Index (QUICKI) are based on single-time fasting glucose and insulin assessment. Their value and discriminatory power in comparison to dynamic range assessment of Si by minimal modelling are not well established. METHODS AND
RESULTS: In 105 patients with stable CHF (mean age 62 ± 1 years, peak VO(2) 18.2 ± 0.7 mL/kg/min, LVEF 28 ± 2%, mean ± SEM) Si was assessed by minimal modelling. HOMA, FIRI, and QUICKI were calculated from single-time point fasting glucose and insulin measurements. Detailed body composition was analyzed using dual-energy X-ray absorptiometry. All assessment methods showed impaired Si in CHF patients compared to healthy controls (n = 25). Yet, only minimal model-derived Si differentiated between NYHA classes (p = 0.0007). Further, minimal modelling was the only method to be directly associated with peak oxygen uptake and skeletal muscle strength. Model-derived Si predicted survival independently of established prognostic markers in CHF (RR 0.30 [95%CI 0.14-0.63]; p = 0.0016). In contrast, HOMA, FIRI and QUICKI did not show any of these qualities.
CONCLUSION: HOMA, FIRI and QUICKI are surrogate estimates of Si with reduced discriminatory power in patients with CHF. While they are suitable to semi-quantitatively categorize impaired Si compared to normal values, the dynamic range assessment of Si by minimal modelling is superior for quantitative assessment of Si in pathophysiological studies.
Copyright © 2009 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19733925     DOI: 10.1016/j.ijcard.2009.07.030

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  7 in total

Review 1.  Glutamate synthase: a fascinating pathway from L-glutamine to L-glutamate.

Authors:  R H H van den Heuvel; B Curti; M A Vanoni; A Mattevi
Journal:  Cell Mol Life Sci       Date:  2004-03       Impact factor: 9.261

Review 2.  Biomarkers for chronic heart failure : diagnostic, prognostic, and therapeutic challenges.

Authors:  Mitja Lainscak; Markus S Anker; Stephan von Haehling; Stefan D Anker
Journal:  Herz       Date:  2009-12       Impact factor: 1.443

3.  Research on cachexia, sarcopenia and skeletal muscle in cardiology.

Authors:  Andrew J S Coats
Journal:  J Cachexia Sarcopenia Muscle       Date:  2012-11-16       Impact factor: 12.910

4.  Fibroblast growth factor 21 in patients with cardiac cachexia: a possible role of chronic inflammation.

Authors:  Maria Refsgaard Holm; Heidi Christensen; Jon Rasmussen; Marie Louise Johansen; Morten Schou; Jens Faber; Caroline Kistorp
Journal:  ESC Heart Fail       Date:  2019-08-20

5.  Metformin protects against insulin resistance induced by high uric acid in cardiomyocytes via AMPK signalling pathways in vitro and in vivo.

Authors:  Zhenyu Jiao; Yingqun Chen; Yang Xie; Yanbing Li; Zhi Li
Journal:  J Cell Mol Med       Date:  2021-05-30       Impact factor: 5.310

6.  Investigation of changes in body composition, metabolic profile and skeletal muscle functional capacity in ischemic stroke patients: the rationale and design of the Body Size in Stroke Study (BoSSS).

Authors:  Michael Knops; Claudia G Werner; Nadja Scherbakov; Jochen Fiebach; Jens P Dreier; Andreas Meisel; Peter U Heuschmann; Gerd J Jungehülsing; Stephan von Haehling; Ulrich Dirnagl; Stefan D Anker; Wolfram Doehner
Journal:  J Cachexia Sarcopenia Muscle       Date:  2013-03-13       Impact factor: 12.910

Review 7.  Cardiac cachexia: hic et nunc.

Authors:  Goran Loncar; Jochen Springer; Markus Anker; Wolfram Doehner; Mitja Lainscak
Journal:  J Cachexia Sarcopenia Muscle       Date:  2016-07-01       Impact factor: 12.910

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.